Morepen Laboratories Ltd
Morepen Laboratories Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY25 call signalled
1 of 4 strong
The short version
The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
From Morepen Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.
- Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment.
- API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues.
- Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business.
- Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to deliver strong growth given health awareness trends.
- The new molecule contribution in API is rising, forecasting faster growth in this segment.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26.
- After the 600 KL capacity expansion, there are no immediate plans for further capacity increases.
- The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes.
- Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has 600 KL capacity planned for FY '26, expected to be completed within the year.
- Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted).
- They are working on building a good outsourcing partner network to manage excess demand or capacity shortage.
- Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake.
- Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues.
- Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to recent raw material price increases and global market conditions.
2 more points management made on order book & pipeline
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Frequently Asked Questions
What were Morepen Laboratories Ltd Q4 FY25 results?
The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 35.9 with a market cap of ₹4,216 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26. - After the 600 KL capacity expansion, there are no immediate plans for further capacity increases. - The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes. - Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins. - There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.